These Doctors Say:
Dr. Frank
Woodbine, Ph.D.:
“Pure
Collagen stimulates a source of natural energy in the body and
those who are taking it are becoming self-evident testimonies to the power of
this incredible wellness resource. There is no need to “try-out” this product.
It is an important source of nutrition for all bodies alike and it works.”
Dr. Bill Trusak, D.C. :
“I’ve been a chiropractor for the past 28 years and currently run a clinic
that sees 200 people a day...I’m so thrilled to expand my practice with a
product that safely and naturally helps people. I know I can recommend pure
collagen and expect tremendous results for my patients.”
Dr. Edward Lafontaine :
“There is nothing on the market like
collagen. I
have been looking for a
collagen based product for over 20 years. I have
repeatedly asked manufacturers to formulate a product like pure
collagen to no avail...This is the one fundamental nutrient I
recommend to each and every patient.”
Ron Darling, Health Practitioner:
“I have had the good fortune of monitoring over 300 patients over a one year
period on the use of the product...They included people with high blood
pressure, arthritis and many more conditions. Over that one year my patients
averaged 85% of positive results...Pure
collagen is very reliable and safe.”
University of Tennessee,
Memphis, USA.
OBJECTIVE: Joint inflammation in juvenile rheumatoid arthritis (JRA)
is sometimes associated with an autoimmune response to type II
collagen (CII), a cartilage-specific protein. To test the
hypothesis that down-regulation of autoimmunity to CII can be accomplished in
JRA by oral administration of CII, an open-label study of CII was performed in
9 patients with JRA....RESULTS:
Eight patient trials met the criteria for clinical improvement outlined by
Giannini and coworkers in 1997. None of the patients had any side effects from
the treatment.
In 6 of the 8 patients
who improved, interferon-gamma production decreased after oral CII therapy,
correlating with clinical improvement, while 6 patients had increases in
levels of transforming growth factor beta3. CONCLUSION: These results are
encouraging.
Beth Israel Deaconess
Medical Center, Boston, Massachusetts 02215, USA.
OBJECTIVE:
Oral administration of
cartilage-derived type II
collagen
(CII) has been shown to ameliorate arthritis
in animal models of joint inflammation, and preliminary
studies have suggested that this novel therapy is clinically beneficial and
safe in patients with rheumatoid arthritis (RA). The present study was
undertaken to test the safety and efficacy of 4 different dosages of orally
administered CII in patients with RA....No treatment-related adverse events
were detected. The efficacy seen with the lowest dosage is consistent with the
findings of animal studies and with known mechanisms of oral tolerance in
which lower doses of orally administered autoantigens preferentially induce
disease-suppressing regulatory cells. CONCLUSION:
Positive
effects were observed with CII at the lowest dosage tested,
and the presence of serum antibodies to CII at baseline may predict
response to therapy. No side effects were associated with this novel
therapeutic agent.
Rheumatism Research Center, Catholic Research Institute of Medical
Science, The Catholic University of Korea, Seoul, Korea.
Induction of oral tolerance has long been considered a promising
approach to the treatment of chronic autoimmune diseases, including rheumatoid
arthritis (RA).
Oral administration of
type II
collagen
(CII) has been proven to improve signs and symptoms in RA patients
without troublesome toxicity. To investigate the mechanism of immune
suppression mediated by orally administered antigen, we examined changes in
serum IgG subtypes and T-cell proliferative responses to CII, and generation
of IL-10-producing CD4+CD25+ T-cell subsets in an animal model of
collagen-induced arthritis (CIA).....
These data suggest that when
these IL-10-producing CD4+CD25+ T cells encounter CII (Collagen type II) antigen in affected
joints they become activated to exert an anti-inflammatory effect.
Department of Rheumatology, University Hospital Jean Minjoz, Bd A.
Fleming, F-25030 Besancon Cedex, France.
Oral tolerance (OT) consists of the oral administration of antigens
(Ag) that could alter the response of the immune system...In Rheumatoid
Arthritis, 4 trials of oral type II
collagen (CII)
in RA have been published. Taken together, these studies suggested that
oral CII in RA gave a trend
toward clinical improvement...
Institute of Clinical Pharmacology, Anhui Medical University, Hefei,
China.
The objective of this study was to investigate the effect of the oral
administration of type II
collagen (CII)
on pro-inflammatory mediator production by synoviocytes in rats with adjuvant
arthritis (AA). Sprague-Dawley rats were fed with bovine CII either before
immunization with Complete Freund's adjuvant (CFA) or after initiation of
arthritis....We
conclude that oral administration of CII (type II
collagen)
had prophylactic and therapeutic effects on AA
and over-production of IL-1, TNF, NO and MDA by
synoviocytes was suppressed. Bystander active suppression may be the
main mechanism of oral CII in the suppression of synoviocyte function.
Guy's Kings, Hospital School of Medicine, King's College, London, UK.
OBJECTIVE: Previous randomized controlled trials for treatment of
rheumatoid arthritis (RA) with acid-soluble chicken and bovine type II
collagen (CII) have produced conflicting results. This
randomized, double-blind, controlled trial examined the therapeutic effect of
bovine CII tablets in RA....There were no side effects associated with CII
treatment. CONCLUSION:
Treatment
with 0.5 mg/day of bovine CII is well tolerated and produces small, but
significant, disease improvement in Rheumatoid Arthritis....The
difference between our results and those of other trials may relate to
the dose, species, and formulation of the CII.
CEPROCOR (Centro de Excelencia en Productos y Procesos de Cordoba),
Argentina.
We evaluated the efficacy and safety of orally administered bovine
tracheal type II
collagen (CGII)
in the treatment of rheumatoid arthritis (RA). Twenty RA patients received 0.5
mg/day of CGII for 12 weeks. Eighteen of them had improvements in the clinical
parameters studied (swollen and tender joint counts, 15-m walking time,
duration of morning stiffness, and physician's global assessment of disease
activity)....Although a placebo effect cannot be discounted,
the oral administration of bovine tracheal CGII induced clinical benefits in
90% of the patients, without the side effects usually associated with
treatment.
This is the first study
showing that feeding CGII can induce reductions in RF and TNF-alpha.
Department of Microbiology, Saga Medical School, Japan.
Oral administration of type II
collagen
(CII) has been shown to suppress
collagen-induced
arthritis (CIA) in experimental
animals...Thus, the neutralization of IL-4 by an anti-IL-4 Ab appears to be
effective in blocking suppression of CIA by oral administration of CII,
suggesting that IL-4 may be critically involved in its suppression.
Department of Orthopedic Surgery, Kansai Medical University.
The correlation between the efficacy of type II
collagen (C
II) treatment of the rheumatoid arthritis (RA) and the existence of HLA-DRB 1
* 0405 allele was investigated in two groups of patients....We concluded that
oral C II could have a therapeutic efficacy in RA patients
with HLA-DRB 1 * 0405
allele.
Department of Microbiology, Saga Medical School, Japan.
The present study was designed to investigate the efficacy of oral
administration of type II
collagen (CII)
on non-specifically induced chronic arthritis in rats, induced by intra-articular
injection of a mineral oil, squalene. When CII was fed before injection of
squalene, no chronic arthritis developed. Feeding CII after the induction of
arthritis was also effective in suppressing the progression of chronic joint
inflammation. In rats fed and primed with CII, there was a decrease in
proliferative responses to CII. Arthritis induced by the mineral oil was
markedly suppressed by the spleen cells from animals fed CII.
These results indicate that non-specifically induced arthritis may be
downregulated by the oral administration of CII
Brigham and Women's Hospital, Boston, MA 02115, USA.
OBJECTIVE. To assess the effect of orally administered type II
collagen (CII) in antigen-induced arthritis (AIA)...RESULTS.
Joint swelling was significantly reduced at a dose of 3 micrograms and 30
micrograms of CII...CONCLUSION.
Oral CII can suppress arthritis
in an animal model in
which immunity to
collagen does not play a role. The effect is dose
dependent and occurs at lower doses of CII. These results demonstrate the
biologic relevance of bystander suppression associated with oral tolerance,
and the potential use of this approach to treat human inflammatory joint
disease.
Department of Medicine, Beth Israel Hospital, Boston, MA.
Rheumatoid arthritis is an inflammatory synovial disease thought to involve T
cells reacting to an antigen within the joint. Type II
collagen is
the major protein in articular cartilage and is a potential autoantigen in
this disease....Four
patients in the
collagen
group had complete
remission of the disease. No side effects were evident. These data demonstrate
clinical efficacy of an oral tolerization approach for rheumatoid arthritis.
Infection & Immunity Group, King's College London, U.K.
The oral administration of CII by gavage to WA/KIR rats
before a conventional arthritogenic challenge with bovine CII in FIA reduced
the incidence (by 23%) and delayed the onset of
collagen-induced
arthritis in about 50% of the animals
